Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial.

30 Emicizumab injection site might have played a role, because during the first 5 weekly administrations in HAVEN 7 when emicizumab injection sites were recorded, 80% of administrations were in the thigh, and a numerical trend for higher exposure after thigh injection than after abdomen or upper arm has been observed in a study of the relative bioavailability of emicizumab across injection sites. 39 In contrast to the higher exposure, analysis of coagulation biomarkers in HAVEN 7 indicates that, at the same emicizumab concentration, TG and FVIII-like activity are somewhat lower in infants than in older populations 40 ; therefore, the hemostatic effect of emicizumab is expected to be correspondingly lower.

also in 665 other papers